dextroamphetamine has been researched along with Body Weight in 176 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Lisdexamfetamine dimesylate offered beneficial effects on body weight, body mass index and several metabolic parameters." | 9.17 | The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. ( Almagor, D; Alsuwaidan, M; Bilkey, TS; Cha, DS; Gallaugher, LA; Kennedy, SH; McIntyre, RS; Powell, AM; Soczynska, JK; Szpindel, I; Woldeyohannes, HO, 2013) |
| " Lisdexamfetamine dimesylate offered beneficial effects on body weight, body mass index and several metabolic parameters." | 5.17 | The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. ( Almagor, D; Alsuwaidan, M; Bilkey, TS; Cha, DS; Gallaugher, LA; Kennedy, SH; McIntyre, RS; Powell, AM; Soczynska, JK; Szpindel, I; Woldeyohannes, HO, 2013) |
| "The effect of dextroamphetamine sulfate (Dexedrine) on plasma opioid peptides, hormones, and other metabolites was studied in eight female subjects with idiopathic (orthostatic) edema and five healthy females." | 3.69 | Opioid peptides, adrenocorticotrophic hormone, and idiopathic (orthostatic) edema. ( Bhathena, SJ; Canary, JJ; Gannon, CA; Glen, ML; Kennedy, BW; Smith, PM; Werman, MJ, 1994) |
| " When challenged with harmine, a known tremorogen with putative effects on olivocerebellar pathways, chlordecone-exposed males were less responsive than vehicle-exposed littermates in a spectral analysis of movement." | 3.67 | Evaluation of long-term consequences in behavioral and/or neural function following neonatal chlordecone exposure. ( Mactutus, CF; Tilson, HA, 1985) |
| "Adult female rats that underwent sympathectomy induced by guanethidine treatment (10, 20 or 40 mg/kg) exhibited markedly increased water intake, but did not display significant alterations of either food intake, body weight, or the Lee Index of obesity." | 3.67 | Effects of guanethidine sympathectomy on feeding, drinking, weight gain and amphetamine anorexia in the rat. ( Clark, DE; Freeman, PH; Wellman, PJ, 1985) |
| "Data from a large prospective study were analyzed to determine if taking dextroamphetamine during pregnancy affects fetal growth or fetal/neonatal mortality." | 3.66 | Maternal use of dextroamphetamine and growth of the fetus. ( Naeye, RL, 1983) |
| "The hyperphagia characteristic of some types of obesity may result from a deficiency in one or more components of the systems controlling satiety which in rats may include the gastrointestinal hormone cholecystokinin (CCK)." | 3.66 | Cholecystokinin, amphetamine and diazepam and feeding in lean and obese Zucker rats. ( Baile, CA; McLaughlin, CL, 1979) |
| "Risperidone-treated patients had clinically and statistically significant reductions in both disruptive behavior and hyperactivity subscale scores, compared to placebo, regardless of concomitant stimulant use." | 2.71 | Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. ( Aman, MG; Binder, C; Turgay, A, 2004) |
| "The dextroamphetamine group was superior in terms of behavioral treatment participation, extent of eating and exercise habit change, and weight loss." | 2.65 | Double-blind evaluation of reinforcing and anorectic actions of weight control medications. Interaction of pharmacological and behavioral treatments. ( Bigelow, GE; Griffiths, RR; Kaliszak, JE; Liebson, I, 1980) |
| "Fenfluramine was particularly effective in alleviating anxiety in patients who were initially higher in anxiety." | 2.64 | Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine. ( Fisher, E; Hesbacher, P; Perloff, MM; Rickels, K; Rosenfeld, H, 1976) |
| " Our LDX dosing regimen yielded blood levels of dextroamphetamine comparable to those documented in patients." | 1.43 | Longitudinal magnetic resonance imaging reveals striatal hypertrophy in a rat model of long-term stimulant treatment. ( Bansal, R; Biezonski, D; Cha, J; Duan, Y; Gerum, S; Guilfoyle, DN; Hrabe, J; Kellendonk, C; Krivko, A; Leventhal, BL; Peterson, BS; Posner, J; Shah, R; Xie, S, 2016) |
| " A treatment history of high AMPH dosage was associated with a marked sensitization of the exploratory behavior in adults, whereas it induced a quite opposite profile in periadolescents." | 1.31 | Striatal dopamine sensitization to D-amphetamine in periadolescent but not in adult rats. ( Laviola, G; Pascucci, T; Pieretti, S, 2001) |
| " On PND 8, unisexually reared females showed, upon maternal deprivation, a generalized shift to the left in the dose-response curve to AMPH for Crossing behaviour, while on PND 18 AMPH-induced stereotypies were considerably reduced in sexually segregated females, especially following maternal deprivation." | 1.30 | Sexual segregation in infant mice: behavioural and neuroendocrine responses to d-amphetamine administration. ( Adriani, W; Cirulli, F; Laviola, G, 1997) |
| " Three groups of four rats each were used: control, d-amphetamine sulphate dosed (s." | 1.30 | Effect of d-amphetamine repeated administration on rat antioxidant defences. ( Carvalho, F; de Lourdes Bastos, M; Fernandes, E; Remião, F, 1999) |
| "Loss of body weight was unaccompanied by parallel changes in operant behavior performance, or in food or water intake." | 1.28 | Super-reactivity to amphetamine toxicity induced by schedule of reinforcement. ( Valencia-Flores, M; Velázquez-Martínez, DN; Villarreal, JE, 1990) |
| "Indomethacin (5 mg/kg, IP) was found to be without direct effect upon fixed-ratio behavior or rectal temperature, but significantly enhanced the capacity of low doses of d-amphetamine to suppress behavior and lower temperature." | 1.27 | Indomethacin potentiates the operant behavior suppressant and rectal temperature lowering effects of low doses of d-amphetamine in rats. ( Nielsen, JA; Sparber, SB, 1984) |
| "Caffeine pretreatment was studied for its effects on d-amphetamine-induced locomotor activity." | 1.27 | Caffeine pretreatment: enhancement and attenuation of d-amphetamine-induced activity. ( Keller, GE; White, BC, 1984) |
| "3." | 1.27 | Effect of three anorectic drugs on central catecholamine levels and synthesis in the Zucker rat. ( Bremond, J; Cohen, Y; Jacquot, C; Orosco, M, 1983) |
| "This study compared the effects of chronic administration of anorexigenic drugs on weight loss in mice." | 1.27 | An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. ( Flood, JF; Morley, JE, 1987) |
| " Behavioral testing, 2 days to 4 mo post-treatment, indicated that DMSO and/or 50 mg/kg of BPAU retarded habituation of spontaneous exploratory activity, impaired acquisition of conditioned (auto-shaped) behavior, and changed the dose-response relationship ford-amphetamine-induced suppression of operant (fixed ratio 32) responding." | 1.27 | Long lasting behavioral effects of dimethyl sulfoxide and the "peripheral" toxicant p-bromophenylacetylurea. ( Fossom, LH; Messing, RB; Sparber, SB, 1985) |
| "Body weight was monitored for 28 days after the infusion, after which rats were first tested in an exploration choice-box and then underwent a series of pharmacological challenges." | 1.27 | Comparative effects of infusions of 6-hydroxydopamine into nucleus accumbens and anterolateral hypothalamus induced by 6-hydroxydopamine on the response to dopamine agonists, body weight, locomotor activity and measures of exploration in the rat. ( Robbins, TW; Winn, P, 1985) |
| "Chlordecone-exposed rats were affected the same as controls by d-amphetamine (0." | 1.26 | Neurobehavioral effects following a single dose of chlordecone (Kepone) administered neonatally to rats. ( Burne, TA; Squibb, RE; Tilson, HA, 1982) |
| "Male and female rats of the Fischer Strain were dosed with 550 mg/kg of benzene or corn oil vehicle on Days 9, 11 and 13 postpartum." | 1.26 | Postnatal exposure to benzene alters the neurobehavioral functioning of rats when tested during adulthood. ( Meyer, OA; Sparber, SB; Squibb, RE; Tilson, HA, 1980) |
| " This temporary effect on growth is present during the first few years of treatment and seems related to drug dosage and to the presence or absence of drug holidays." | 1.26 | The effects of stimulant medication on the growth of hyperkinetic children. ( Hung, W; Lipman, RS; Overall, JE; Roche, AF, 1979) |
| " Total daily drug intake was related to the unit dose delivered per injection in that a higher drug dosage led to more drug intake." | 1.26 | Intravenous self-administration of drugs in rats. ( de Wied, D; Slangen, JL; van Ree, JM, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 139 (78.98) | 18.7374 |
| 1990's | 20 (11.36) | 18.2507 |
| 2000's | 10 (5.68) | 29.6817 |
| 2010's | 7 (3.98) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cox, MT | 1 |
| Jaggers, SE | 1 |
| Jones, G | 1 |
| Hudzik, TJ | 1 |
| Basso, AM | 1 |
| Lynch, JJ | 1 |
| Bracken, WM | 1 |
| Mohler, EG | 1 |
| Kohlhaas, KL | 1 |
| Xu, H | 1 |
| Haig, G | 1 |
| Gault, L | 1 |
| McIntyre, RS | 1 |
| Alsuwaidan, M | 1 |
| Soczynska, JK | 1 |
| Szpindel, I | 1 |
| Bilkey, TS | 1 |
| Almagor, D | 1 |
| Woldeyohannes, HO | 1 |
| Powell, AM | 1 |
| Cha, DS | 1 |
| Gallaugher, LA | 1 |
| Kennedy, SH | 1 |
| Poulton, AS | 1 |
| Bui, Q | 1 |
| Melzer, E | 1 |
| Evans, R | 1 |
| Kõiv, K | 1 |
| Metelitsa, M | 1 |
| Vares, M | 1 |
| Tiitsaar, K | 1 |
| Raudkivi, K | 1 |
| Jaako, K | 1 |
| Vulla, K | 1 |
| Shimmo, R | 1 |
| Harro, J | 1 |
| Biezonski, D | 1 |
| Shah, R | 1 |
| Krivko, A | 1 |
| Cha, J | 1 |
| Guilfoyle, DN | 1 |
| Hrabe, J | 1 |
| Gerum, S | 1 |
| Xie, S | 1 |
| Duan, Y | 1 |
| Bansal, R | 1 |
| Leventhal, BL | 1 |
| Peterson, BS | 1 |
| Kellendonk, C | 1 |
| Posner, J | 1 |
| Faraone, SV | 1 |
| Spencer, TJ | 1 |
| Kollins, SH | 1 |
| Glatt, SJ | 1 |
| Pinheiro, RM | 1 |
| de Lima, MN | 1 |
| Fries, GR | 1 |
| Garcia, VA | 1 |
| Presti-Torres, J | 1 |
| Hallmenschlager, LH | 1 |
| Alcalde, LA | 1 |
| Roesler, R | 1 |
| Andersen, ML | 1 |
| Quevedo, J | 1 |
| Kapczinski, F | 1 |
| Schröder, N | 1 |
| Negus, SS | 1 |
| Mello, NK | 1 |
| Poulton, A | 1 |
| Cowell, CT | 1 |
| SPELLER, PJ | 1 |
| STREETEN, DH | 2 |
| JOHANNESSEN, SG | 1 |
| Aman, MG | 1 |
| Binder, C | 1 |
| Turgay, A | 1 |
| McDougall, SA | 1 |
| Hernandez, RM | 1 |
| Reichel, CM | 1 |
| Farley, CM | 1 |
| Lutz, P | 1 |
| Gralewicz, S | 1 |
| Kur, B | 1 |
| Wiaderna, D | 1 |
| Peleg-Raibstein, D | 1 |
| Sydekum, E | 1 |
| Feldon, J | 1 |
| Hao, J | 1 |
| Cabeza de Vaca, S | 1 |
| Pan, Y | 1 |
| Carr, KD | 1 |
| Lovic, V | 1 |
| Fleming, AS | 1 |
| Fletcher, PJ | 1 |
| Evenden, J | 1 |
| Ko, T | 1 |
| COOPERSMITH, BI | 1 |
| Vacher, J | 1 |
| Lakatos, C | 1 |
| Rispat, G | 1 |
| Duchêne-Marullaz, P | 1 |
| Johnson, GA | 2 |
| Kim, EG | 1 |
| Veldkamp, W | 3 |
| Russell, R | 1 |
| Keasling, HH | 1 |
| Freyburger, WA | 1 |
| Collins, RJ | 1 |
| Kavale, K | 1 |
| Squibb, RE | 3 |
| Tilson, HA | 5 |
| Burne, TA | 1 |
| Harsing, LG | 1 |
| Yang, HY | 1 |
| Govoni, S | 1 |
| Costa, E | 1 |
| Tordoff, MG | 1 |
| Novin, D | 1 |
| Russek, M | 1 |
| Robbins, TW | 3 |
| Roberts, DC | 1 |
| Koob, GF | 1 |
| Demellweek, C | 1 |
| Goudie, AJ | 2 |
| Jänicke, B | 1 |
| Wrobel, D | 1 |
| Nielsen, JA | 1 |
| Sparber, SB | 5 |
| Golinko, BE | 2 |
| Stewart, JW | 1 |
| Quitkin, F | 1 |
| McGrath, PJ | 1 |
| Liebowitz, MR | 1 |
| Harrison, W | 1 |
| Rabkin, JG | 1 |
| Novacenko, H | 1 |
| Puig-Antich, J | 1 |
| Asnis, GM | 1 |
| Wolgin, DL | 3 |
| Ettinger, RH | 1 |
| Staddon, JE | 1 |
| Rafales, LS | 3 |
| Lasley, SM | 2 |
| Greenland, RD | 1 |
| Mandybur, T | 1 |
| White, BC | 1 |
| Keller, GE | 1 |
| Monder, H | 1 |
| Hunsinger, RN | 1 |
| Barnes, TB | 1 |
| Kapeghian, JC | 1 |
| Wilson, MC | 1 |
| Naeye, RL | 1 |
| Hill, DT | 1 |
| Stanley, KG | 1 |
| Williams, JE | 1 |
| Loev, B | 1 |
| Fowler, PJ | 1 |
| McCafferty, JP | 1 |
| Macko, E | 1 |
| Berkoff, CE | 1 |
| Ladd, CB | 1 |
| Orosco, M | 1 |
| Bremond, J | 1 |
| Jacquot, C | 1 |
| Cohen, Y | 1 |
| Bigelow, GE | 2 |
| Griffiths, RR | 2 |
| Liebson, I | 2 |
| Kaliszak, JE | 1 |
| Stunkard, AJ | 1 |
| Reed, CF | 1 |
| Witt, PN | 1 |
| Scarboro, MB | 1 |
| Zenick, H | 1 |
| Greenland, R | 1 |
| Caruso, V | 1 |
| Succop, P | 1 |
| Price, D | 1 |
| Michaelson, IA | 3 |
| Kuprys, R | 1 |
| Oltmans, GA | 1 |
| Lewis, MJ | 1 |
| Kanarek, RB | 2 |
| Concannon, JT | 1 |
| Schechter, MD | 1 |
| Wellman, PJ | 2 |
| Peters, RH | 1 |
| Dolinsky, Z | 1 |
| Fink, E | 1 |
| Burright, RG | 1 |
| Donovick, PJ | 1 |
| Meyer, OA | 1 |
| Cooper, BR | 1 |
| Howard, JL | 1 |
| White, HL | 1 |
| Soroko, F | 1 |
| Ingold, K | 1 |
| Maxwell, RA | 1 |
| Schmidt, ME | 1 |
| Kruesi, MJ | 1 |
| Elia, J | 1 |
| Borcherding, BG | 1 |
| Elin, RJ | 1 |
| Hosseini, JM | 1 |
| McFarlin, KE | 1 |
| Hamburger, S | 1 |
| Lyon, M | 1 |
| McClure, WO | 1 |
| Bronson, ME | 1 |
| Jiang, W | 1 |
| Clark, CR | 1 |
| DeRuiter, J | 1 |
| Bhathena, SJ | 1 |
| Canary, JJ | 1 |
| Smith, PM | 1 |
| Glen, ML | 1 |
| Gannon, CA | 1 |
| Kennedy, BW | 1 |
| Werman, MJ | 1 |
| Inglis, WL | 1 |
| Allen, LF | 1 |
| Whitelaw, RB | 1 |
| Latimer, MP | 1 |
| Brace, HM | 1 |
| Winn, P | 3 |
| Hughes, HE | 1 |
| Donohue, LM | 1 |
| Dow-Edwards, DL | 1 |
| Cirulli, F | 1 |
| Adriani, W | 2 |
| Laviola, G | 3 |
| Chiarotti, F | 1 |
| Nation, JR | 1 |
| Miller, DK | 1 |
| Carvalho, F | 1 |
| Fernandes, E | 1 |
| Remião, F | 1 |
| de Lourdes Bastos, M | 1 |
| Hughes, KM | 1 |
| Popi, L | 1 |
| Pascucci, T | 1 |
| Pieretti, S | 1 |
| Kaliszak, J | 1 |
| Chou, SM | 1 |
| Miike, T | 1 |
| Payne, WM | 1 |
| Davis, GJ | 1 |
| Tyler, TD | 1 |
| Tessel, RE | 1 |
| Creese, I | 2 |
| Iversen, SD | 3 |
| Pinals, RS | 1 |
| Dalakos, TG | 1 |
| Bailey, RC | 1 |
| Jackson, DM | 1 |
| McLaughlin, CL | 1 |
| Baile, CA | 1 |
| Bornschein, RL | 2 |
| Loch, RK | 2 |
| Barker, GF | 1 |
| Roche, AF | 1 |
| Lipman, RS | 1 |
| Overall, JE | 1 |
| Hung, W | 1 |
| Clemens, LG | 1 |
| Popham, TV | 1 |
| Ruppert, PH | 1 |
| Cabe, PA | 1 |
| Ellinwood, EH | 1 |
| Gonzalez, LP | 1 |
| Thornhill, JA | 1 |
| Hirst, M | 1 |
| Gowdey, CW | 1 |
| Schreiber, H | 1 |
| Bell, R | 1 |
| Wood, G | 1 |
| Carlson, R | 1 |
| Wright, L | 1 |
| Kufner, M | 1 |
| Villescas, R | 1 |
| Marshall, JF | 1 |
| Yehuda, S | 1 |
| Carasso, RL | 1 |
| van Ree, JM | 1 |
| Slangen, JL | 1 |
| de Wied, D | 1 |
| Holl, JE | 1 |
| Resurreccion, AV | 1 |
| Park, LE | 1 |
| Caster, WO | 1 |
| Takahashi, RN | 1 |
| Singer, G | 1 |
| Oei, TP | 1 |
| Arnold, LE | 2 |
| Huestis, RD | 1 |
| Smeltzer, DJ | 1 |
| Scheib, J | 1 |
| Wemmer, D | 1 |
| Colner, G | 1 |
| Rickels, K | 2 |
| Hesbacher, P | 2 |
| Fisher, E | 1 |
| Perloff, MM | 1 |
| Rosenfeld, H | 1 |
| Davies, RF | 1 |
| Le Moal, M | 1 |
| Stinus, L | 1 |
| Simon, H | 1 |
| Tassin, JP | 1 |
| Thierry, AM | 1 |
| Blanc, G | 1 |
| Glowinski, J | 1 |
| Cardo, B | 1 |
| Abdallah, AH | 2 |
| Nagasawa, S | 1 |
| Burklund, KE | 1 |
| Danielson, TJ | 1 |
| Wishart, TB | 2 |
| Boulton, AA | 1 |
| Sahakian, BJ | 1 |
| Sever, PS | 1 |
| Caldwell, J | 1 |
| Williams, RT | 1 |
| Milloy, S | 1 |
| Glick, SD | 1 |
| Gay, PE | 1 |
| Cole, SO | 1 |
| Safer, DJ | 2 |
| Allen, RP | 2 |
| Barr, E | 2 |
| Magour, S | 4 |
| Coper, H | 5 |
| Mabry, PD | 1 |
| Campbell, BA | 2 |
| Zemp, JW | 2 |
| Middaugh, LD | 2 |
| Abbatiello, ER | 1 |
| Daly, I | 1 |
| Thornton, EW | 1 |
| Janssen, PA | 1 |
| Niemegeers, CJ | 1 |
| Schellekens, KH | 1 |
| Lenaerts, FM | 1 |
| Wauquier, A | 1 |
| Fähndrich, CH | 1 |
| Jones, JR | 3 |
| Caul, WF | 3 |
| Weissenborn, R | 1 |
| Hill, JO | 1 |
| Drucker-Colín, R | 1 |
| García-Hernández, F | 1 |
| Mucha, RF | 1 |
| Walker, MJ | 1 |
| Fassos, FF | 1 |
| Thurmond, JB | 1 |
| Freeman, GB | 1 |
| Soblosky, JS | 1 |
| Ieni, JR | 1 |
| Brown, JW | 1 |
| Cherek, DR | 1 |
| Steinberg, JL | 1 |
| Kelly, TH | 1 |
| Robinson, DE | 1 |
| Spiga, R | 1 |
| Coveney, JR | 1 |
| Valencia-Flores, M | 1 |
| Velázquez-Martínez, DN | 1 |
| Villarreal, JE | 1 |
| Mactutus, CF | 1 |
| Dahl, CB | 1 |
| Götestam, KG | 1 |
| Nichols, MB | 1 |
| Maickel, RP | 1 |
| French, ED | 1 |
| Jacobson, AE | 1 |
| Rice, KC | 1 |
| Krishnan, KR | 1 |
| Manepalli, AN | 1 |
| Ritchie, JC | 1 |
| Rayasam, K | 1 |
| Melville, ML | 1 |
| Daughtry, G | 1 |
| Thorner, MO | 1 |
| Rivier, JE | 1 |
| Vale, WW | 1 |
| Nemeroff, CB | 1 |
| Morley, JE | 1 |
| Flood, JF | 1 |
| Fung, YK | 1 |
| Barker, E | 1 |
| Martinez, TT | 2 |
| Marks-Kaufman, R | 1 |
| Barrett, RJ | 1 |
| Massey, BW | 1 |
| McMillan, DE | 1 |
| Jessen, TG | 1 |
| Lupien, JR | 1 |
| Bray, GA | 2 |
| Leibowitz, SF | 1 |
| Shor-Posner, G | 1 |
| Maclow, C | 1 |
| Grinker, JA | 1 |
| Fossom, LH | 1 |
| Messing, RB | 1 |
| Fisler, JS | 1 |
| Bhakthavatsalam, P | 1 |
| Kamatchi, GL | 1 |
| Ghosh, MN | 1 |
| Salisbury, JJ | 1 |
| Freeman, PH | 1 |
| Clark, DE | 1 |
| Stunkard, A | 1 |
| Green, TK | 1 |
| Harvey, JA | 1 |
| Fähndrich, C | 2 |
| Defelice, EA | 1 |
| Chaykin, LB | 1 |
| Cohen, A | 1 |
| Ziem, M | 1 |
| Broermann, I | 1 |
| Strauss, S | 1 |
| Mathew, G | 1 |
| Lifshitz, F | 1 |
| Shoeman, DW | 1 |
| Sirtori, CR | 1 |
| Azarnoff, DL | 1 |
| Blackwell, LA | 1 |
| Santos, CA | 1 |
| Sofia, RD | 2 |
| Barry, H | 1 |
| Oliver, JT | 1 |
| Ahlskog, JE | 1 |
| Hoebel, BG | 1 |
| Parkes, JD | 1 |
| Fenton, G | 1 |
| Struthers, G | 1 |
| Curzon, G | 1 |
| Kantamaneni, BD | 1 |
| Buxton, BH | 1 |
| Record, C | 1 |
| Safer, D | 1 |
| Allen, R | 1 |
| Wender, PH | 1 |
| McCloskey, K | 1 |
| Snyder, SH | 1 |
| Walls, EK | 1 |
| Noble, RE | 1 |
| Lu, TC | 1 |
| Claghorn, JL | 1 |
| Schoolar, JC | 1 |
| DeFeudis, FV | 1 |
| Marks, JH | 1 |
| Cabezas Cerrato, J | 1 |
| Catalán, E | 1 |
| Vila, T | 1 |
| Fernández-Cruz, A | 1 |
| VanderWende, C | 1 |
| Johnson, JC | 1 |
| Spoerlein, MT | 1 |
| Luc, NC | 1 |
| Vernadakis, A | 2 |
| Robb, D | 1 |
| MacPhail, RC | 1 |
| Gollub, LR | 2 |
| Fibiger, HC | 1 |
| Trimbach, C | 1 |
| Prabhu, VG | 1 |
| Oester, YT | 1 |
| London, AM | 1 |
| Schreiber, ED | 1 |
| Mann, WG | 1 |
| Yelnosky, J | 2 |
| Panasevich, RE | 1 |
| Borrelli, AR | 1 |
| Lawlor, RB | 2 |
| Trivedi, MC | 1 |
| Krivanek, JA | 1 |
| McGaugh, JL | 1 |
| Rudzik, AD | 1 |
| Clark, CV | 1 |
| Gorman, D | 1 |
| Epstein, LC | 1 |
| Lasagna, L | 1 |
| Connors, CK | 1 |
| Rodriguez, A | 1 |
| Alphin, RS | 1 |
| Ward, JW | 1 |
| Uehling, BS | 1 |
| Lewander, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Treatment, 3-Period, Crossover Study With One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR, or Placebo in Children Aged 6 to 12 Years With Attention-Deficit H[NCT00557011] | Phase 2 | 52 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Phase 3, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of NRP104 in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder[NCT00556296] | Phase 3 | 297 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542] | Phase 2 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Subscale I | Visit 3 - First Intervention: Subscale I | Visit 5 - First Intervention: Subscale I | Visit 6 - Second Intervention: Subscale I | Visit 8 - Second Intervention: Subscale I | Visit 10 - Second Intervention: Subscale I | Follow-up: Subscale I (Irritability) | Visit 1 - First Intervention: Subscale II | Visit 3 - First Intervention: Subscale II | Visit 5 - First Intervention: Subscale II | Visit 6 - Second Intervention: Subscale II | Visit 8 - Second Intervention: Subscale II | Visit 10 - Second Intervention: Subscale II | Follow-up: Subscale II (Lethargy) | Visit 1 - First Intervention: Subscale III | Visit 3 - First Intervention: Subscale III | Visit 5 - First Intervention: Subscale III | Visit 6 - Second Intervention: Subscale III | Visit 8 - Second Intervention: Subscale III | Visit 10 - Second Intervention: Subscale III | Follow-up: Subscale III (Stereotypy) | Visit 1 - First Intervention: Subscale IV | Visit 3 - First Intervention: Subscale IV | Visit 5 - First Intervention: Subscale IV | Visit 6 - Second Intervention: Subscale IV | Visit 8 - Second Intervention: Subscale IV | Visit 10 - Second Intervention: Subscale IV | Follow-up: Subscale IV (Hyperactivity) | |
| Placebo First, Then rhIGF-1 | 9.00 | 9.00 | 7.00 | 7.00 | 4.00 | 5.00 | 3.00 | 13.00 | 11.00 | 9.00 | 11.00 | 8.00 | 6.00 | 6.00 | 13.00 | 10.00 | 11.00 | 11.00 | 10.00 | 8.00 | 8.00 | 13.00 | 12.00 | 11.00 | 11.00 | 7.00 | 10.00 | 9.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 2.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 12.00 | 10.00 | 9.00 | 11.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 6.00 | 7.00 | 4.00 | 5.00 | 5.00 |
"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Manic/Hyperactive | Visit 2- First Intervention: Manic/Hyperactive | Visit 3- First Intervention: Manic/Hyperactive | Visit 4- First Intervention: Manic/Hyperactive | Visit 5- First Intervention: Manic/Hyperactive | Visit 6- Second Intervention: Manic/Hyperactive | Visit 7- Second Intervention: Manic/Hyperactive | Visit 8- Second Intervention: Manic/Hyperactive | Visit 9- Second Intervention: Manic/Hyperactive | Visit 10- First Intervention: Manic/Hyperactive | Follow-up: Manic/Hyperactive Subscale | Visit 1- First Intervention: Depressed Mood | Visit 2- First Intervention: Depressed Mood | Visit 3- First Intervention: Depressed Mood | Visit 4- First Intervention: Depressed Mood | Visit 5- First Intervention: Depressed Mood | Visit 6- Second Intervention: Depressed Mood | Visit 7- Second Intervention: Depressed Mood | Visit 8- Second Intervention: Depressed Mood | Visit 9- Second Intervention: Depressed Mood | Visit 10- Second Intervention: Depressed Mood | Follow-up: Depressed Mood Subscale | Visit 1- First Intervention: General Anxiety | Visit 2- First Intervention: General Anxiety | Visit 3- First Intervention: General Anxiety | Visit 4- First Intervention: General Anxiety | Visit 5- First Intervention: General Anxiety | Visit 6- Second Intervention: General Anxiety | Visit 7- Second Intervention: General Anxiety | Visit 8- Second Intervention: General Anxiety | Visit 9- Second Intervention: General Anxiety | Visit 10- Second Intervention: General Anxiety | Follow-up: General Anxiety Subscale | Visit 1- First Intervention: Obsessive Compulsive | Visit 2- First Intervention: Obsessive Compulsive | Visit 3- First Intervention: Obsessive Compulsive | Visit 4- First Intervention: Obsessive Compulsive | Visit 5- First Intervention: Obsessive Compulsive | Visit 6- Second Intervention: Obsessive Compulsive | Visit 7- Second Intervention: Obsessive Compulsive | Visit 8- Second Intervention: Obsessive Compulsive | Visit 9- Second Intervention: Obsessive Compulsive | Visit 10- First Intervention: Obsessive Compulsive | Follow-up: Obsessive Compulsive Behavior Subscale | |
| Placebo First, Then rhIGF-1 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.50 | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 5.50 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.50 | 5.00 | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.50 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.50 | 3.00 |
"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 3.00 |
"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.50 |
"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Social | Visit 2: Social Composite Score | Visit 3: Social Composite Score | Visit 4: Social Composite Score | Visit 5: Social Composite Score | Visit 6 - Second Intervention: Social | Visit 7 - Second Intervention: Social | Visit 8 - Second Intervention: Social | Visit 9 - Second Intervention: Social | Visit 10 - Second Intervention: Social | Follow-up: Social Composite Score | Visit 1 - First Intervention: Speech | Visit 2 - First Intervention: Speech | Visit 3 - First Intervention: Speech | Visit 4 - First Intervention: Speech | Visit 5 - First Intervention: Speech | Visit 6 - Second Intervention: Speech | Visit 7 - Second Intervention: Speech | Visit 8 - Second Intervention: Speech | Visit 9 - Second Intervention: Speech | Visit 10 - Second Intervention: Speech | Follow-up: Speech Composite Score | Visit 1 - First Intervention: Symbolic | Visit 2 - First Intervention: Symbolic | Visit 3 - First Intervention: Symbolic | Visit 4 - First Intervention: Symbolic | Visit 5 - First Intervention: Symbolic | Visit 6 - Second Intervention: Symbolic | Visit 7 - Second Intervention: Symbolic | Visit 8 - Second Intervention: Symbolic | Visit 9 - Second Intervention: Symbolic | Visit 10 - Second Intervention: Symbolic | Follow-up: Symbolic Composite Score | |
| Placebo First, Then rhIGF-1 | 19.00 | 20.00 | 18.00 | 18.00 | 20.00 | 18.00 | 20.00 | 21.00 | 21.00 | 22.50 | 22.50 | 4.00 | 3.00 | 5.00 | 5.50 | 6.50 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 9.50 | 10.50 | 10.50 | 12.00 | 11.50 | 13.00 | 10.25 | 11.50 | 11.50 | 13.75 | 14.25 |
| rhIGF-1 First, Then Placebo | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 28.00 | 25.00 | 27.00 | 29.00 | 27.00 | 28.00 | 7.00 | 5.00 | 8.00 | 5.00 | 8.00 | 8.50 | 7.00 | 6.50 | 5.00 | 7.25 | 6.00 | 14.00 | 14.50 | 15.00 | 14.00 | 16.50 | 18.50 | 17.00 | 17.00 | 18.00 | 17.00 | 18.00 |
"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 16.50 | 15.00 | 15.00 | 14.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 18.00 | 19.00 | 20.00 |
"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Visual Reception | Visit 5- First Intervention: Visual Reception | Visit 6- Second Intervention: Visual Reception | Visit 10: Visual Reception Raw Score | Visit 1- First Intervention: Fine Motor | Visit 5- First Intervention: Fine Motor | Visit 6- Second Intervention: Fine Motor | Visit 10- Second Intervention: Fine Motor | Visit 1- First Intervention: Receptive Language | Visit 5- First Intervention: Receptive Language | Visit 6- Second Intervention: Receptive Language | Visit 10- Second Intervention: Receptive Language | Visit 1- First Intervention: Expressive Language | Visit 5- First Intervention: Expressive Language | Visit 6- Second Intervention: Expressive Language | Visit 10- Second Intervention: Expressive Language | |
| Placebo First, Then rhIGF-1 | 17.00 | 26.00 | 23.00 | 28.00 | 10.00 | 9.00 | 11.00 | 9.00 | 20.00 | 30.00 | 31.00 | 31.00 | 8.00 | 9.00 | 6.00 | 8.00 |
| rhIGF-1 First, Then Placebo | 26.00 | 39.50 | 42.00 | 44.00 | 7.00 | 7.00 | 10.00 | 8.50 | 25.50 | 32.00 | 38.00 | 36.50 | 9.00 | 8.00 | 10.00 | 8.00 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.50 | 4.70 | 5.65 | 5.05 | 4.80 | 4.95 | 4.55 | 5.65 | 4.15 | 4.80 | 5.60 |
| rhIGF-1 First, Then Placebo | 8.80 | 4.80 | 5.35 | 5.10 | 5.15 | 5.20 | 4.65 | 5.00 | 5.15 | 5.05 | 5.08 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.75 | 4.50 | 5.85 | 5.00 | 5.00 | 5.35 | 5.50 | 5.15 | 3.80 | 4.90 | 5.15 |
| rhIGF-1 First, Then Placebo | 6.35 | 5.25 | 5.95 | 5.40 | 5.45 | 7.10 | 5.85 | 5.00 | 5.13 | 4.95 | 5.20 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.85 | 4.70 | 5.65 | 4.15 | 5.00 | 6.20 | 4.80 | 4.85 | 4.60 | 4.13 | 4.55 |
| rhIGF-1 First, Then Placebo | 5.70 | 5.00 | 5.20 | 5.35 | 5.10 | 5.35 | 4.95 | 5.15 | 5.25 | 4.55 | 5.10 |
"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 5.00 | 4.00 |
"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | Apneas/Hour (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Apnea Index | Visit 3 - First Intervention: Apnea Index | Visit 5 - First Intervention: Apnea Index | Visit 6 - Second Intervention: Apnea Index | Visit 8 - Second Intervention: Apnea Index | Visit 10 - Second Intervention: Apnea Index | |
| Placebo First, Then rhIGF-1 | 7.58 | 4.80 | 6.93 | 7.90 | 7.28 | 8.91 |
| rhIGF-1 First, Then Placebo | 4.05 | 3.48 | 3.07 | 3.62 | 5.55 | 5.56 |
"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: General Mood | Visit 2- First Intervention: General Mood | Visit 3- First Intervention: General Mood | Visit 4- First Intervention: General Mood | Visit 5- First Intervention: General Mood | Visit 6- Second Intervention: General Mood | Visit 7- Second Intervention: General Mood | Visit 8- Second Intervention: General Mood | Visit 9- Second Intervention: General Mood | Visit 10- Second Intervention: General Mood | Follow-up: General Mood | Visit 1- First Intervention: Body Rocking | Visit 2- First Intervention: Body Rocking | Visit 3- First Intervention: Body Rocking | Visit 4- First Intervention: Body Rocking | Visit 5- First Intervention: Body Rocking | Visit 6- Second Intervention: Body Rocking | Visit 7- Second Intervention: Body Rocking | Visit 8- Second Intervention: Body Rocking | Visit 9- Second Intervention: Body Rocking | Visit 10- Second Intervention: Body Rocking | Followup: Body Rocking | Visit 1- First Intervention: Hand Behaviors | Visit 2- First Intervention: Hand Behaviors | Visit 3- First Intervention: Hand Behaviors | Visit 4- First Intervention: Hand Behaviors | Visit 5- First Intervention: Hand Behaviors | Visit 6- Second Intervention: Hand Behaviors | Visit 7- Second Intervention: Hand Behaviors | Visit 8- Second Intervention: Hand Behaviors | Visit 9- Second Intervention: Hand Behaviors | Visit 10- Second Intervention: Hand Behaviors | Follow-up: Hand Behaviors | Visit 1- First Intervention: Breathing Problems | Visit 2- First Intervention: Breathing Problems | Visit 3- First Intervention: Breathing Problems | Visit 4- First Intervention: Breathing Problems | Visit 5- First Intervention: Breathing Problems | Visit 6- Second Intervention: Breathing Problems | Visit 7- Second Intervention: Breathing Problems | Visit 8- Second Intervention: Breathing Problems | Visit 9- Second Intervention: Breathing Problems | Visit 10- Second Intervention: Breathing Problems | Follow-up: Breathing Problems | Visit 1- First Intervention: Repetitive Face Movem | Visit 2- First Intervention: Repetitive Face Movem | Visit 3- First Intervention: Repetitive Face Movem | Visit 4- First Intervention: Repetitive Face Movem | Visit 5- First Intervention: Repetitive Face Movem | Visit 6- Second Intervention: Repetitive Face Mov | Visit 7- Second Intervention: Repetitive Face Mov | Visit 8- Second Intervention: Repetitive Face Mov | Visit 9- Second Intervention: Repetitive Face Mov | Visit 10- Second Intervention: Repetitive Face Mov | Follow-up: Repetitive Face Movements | Visit 1- First Intervention: Night time Behaviors | Visit 2- First Intervention: Night time Behaviors | Visit 3- First Intervention: Night time Behaviors | Visit 4- First Intervention: Night time Behaviors | Visit 5- First Intervention: Night time Behaviors | Visit 6- Second Intervention: Night time Behavior | Visit 7- Second Intervention: Night time Behavior | Visit 8- Second Intervention: Night time Behavior | Visit 9- Second Intervention: Night time Behavior | Visit 10- Second Intervention: Night time Behavior | Follow-up: Night time Behaviors | Visit 1- First Intervention: Walking/Standing | Visit 2- First Intervention: Walking/Standing | Visit 3- First Intervention: Walking/Standing | Visit 4- First Intervention: Walking/Standing | Visit 5- First Intervention: Walking/Standing | Visit 6- Second Intervention: Walking/Standing | Visit 7- Second Intervention: Walking/Standing | Visit 8- Second Intervention: Walking/Standing | Visit 9- Second Intervention: Walking/Standing | Visit 10- Second Intervention: Walking/Standing | Follow-up: Walking/Standing | |
| Placebo First, Then rhIGF-1 | 7.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.50 | 5.00 | 6.00 | 4.00 | 5.50 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.50 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.50 | 6.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.50 | 6.00 | 5.00 | 6.00 | 5.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 1.50 | 2.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.50 | 2.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 7.00 | 9.00 | 8.50 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.50 |
"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Receptive | Visit 5 - First Intervention: Receptive | Visit 6 - Second Intervention: Receptive Language | Visit 10 - Second Intervention: Receptive Language | Visit 1 - First Intervention: Expressive | Visit 5 - First Intervention: Expressive | Visit 6 - Second Intervention: Expressive Lang. | Visit 10 - Second Intervention: Expressive Lang. | Visit 1 - First Intervention: Written | Visit 5 - First Intervention: Written | Visit 6: - Second Intervention Written Language | Visit 10 - Second Intervention: Written Language | Visit 1 - First Intervention: Personal | Visit 5 - First Intervention: Personal | Visit 6 - Second Intervention: Personal | Visit 10 - Second Intervention: Personal | Visit 1 - First Intervention: Domestic | Visit 5 - First Intervention: Domestic | Visit 6 - Second Intervention: Domestic | Visit 10 - Second Intervention: Domestic | Visit 1 - First Intervention: Community | Visit 5 - First Intervention: Community | Visit 6 - Second Intervention: Community | Visit 10 - Second Intervention: Community | Visit 1 - First Intervention: Interpersonal Rel. | Visit 5 - First Intervention: Interpersonal Rel. | Visit 6 - Second Intervention: Interpersonal Rel. | Visit 10 - Second Intervention: Interpersonal Rel. | Visit 1 - First Intervention: Play and Leisure | Visit 5 - First Intervention: Play and Leisure | Visit 6 - Second Intervention: Play and Leisure | Visit 10 - Second Intervention: Play and Leisure | Visit 1 - First Intervention: Coping Skills | Visit 5 - First Intervention: Coping Skills | Visit 6 - Second Intervention: Coping Skills | Visit 10 - Second Intervention: Coping Skills | Visit 1 - First Intervention: Gross Motor | Visit 5 - First Intervention: Gross Motor | Visit 6 - Second Intervention: Gross Motor | Visit 10 - Second Intervention: Gross Motor | Visit 1 - First Intervention: Fine Motor | Visit 5 - First Intervention: Fine Motor | Visit 6 - Second Intervention: Fine Motor | Visit 10 - Second Intervention: Fine Motor | |
| Placebo First, Then rhIGF-1 | 13.00 | 15.00 | 18.00 | 20.00 | 16.00 | 17.00 | 18.00 | 20.00 | 0.00 | 0.00 | 4.00 | 6.00 | 9.00 | 10.00 | 9.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 | 18.00 | 18.00 | 19.00 | 20.00 | 8.00 | 11.00 | 12.00 | 11.00 | 3.00 | 2.00 | 3.00 | 4.00 | 31.00 | 34.00 | 27.00 | 27.00 | 6.00 | 6.00 | 7.00 | 5.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 21.00 | 22.00 | 24.50 | 18.00 | 22.00 | 25.00 | 24.00 | 4.00 | 5.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.50 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 5.00 | 5.00 | 21.00 | 22.00 | 21.00 | 22.50 | 13.00 | 12.00 | 13.00 | 12.50 | 3.00 | 4.00 | 6.00 | 4.50 | 10.00 | 10.00 | 11.50 | 10.50 | 2.00 | 3.00 | 4.00 | 4.00 |
3 reviews available for dextroamphetamine and Body Weight
| Article | Year |
|---|---|
The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis.
Topics: Achievement; Attention; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Height; | 1982 |
Anorectic agents lower a body weight set point.
Topics: Animals; Appetite Depressants; Appetite Regulation; Behavior Therapy; Body Weight; Dextroamphetamine | 1982 |
The growth of children given stimulant drugs.
Topics: Appetite; Body Height; Body Weight; Child; Dextroamphetamine; Dose-Response Relationship, Drug; Educ | 1973 |
13 trials available for dextroamphetamine and Body Weight
| Article | Year |
|---|---|
The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Body Weight; Dextroamphetami | 2013 |
Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2004 |
Double-blind evaluation of reinforcing and anorectic actions of weight control medications. Interaction of pharmacological and behavioral treatments.
Topics: Adult; Behavior Therapy; Body Weight; Clinical Trials as Topic; Dextroamphetamine; Double-Blind Meth | 1980 |
Side effects of dexedrine in hyperactive children: operationalization and quantification in a short-term trial.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Body Weight; Child; Dextroamphetamine; Dose | 1982 |
Effect of dextroamphetamine and methylphenidate on calcium and magnesium concentration in hyperactive boys.
Topics: Attention Deficit Disorder with Hyperactivity; Body Weight; Calcium; Child; Circadian Rhythm; Dextro | 1994 |
Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Weight; Child; Clin | 1976 |
Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine.
Topics: Adult; Anxiety; Body Weight; Clinical Trials as Topic; Depression; Dextroamphetamine; Emotions; Fema | 1976 |
Fenfluramine in the treatment of obesity.
Topics: Adult; Appetite Depressants; Body Weight; Clinical Trials as Topic; Constipation; Dextroamphetamine; | 1973 |
Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity.
Topics: Adult; Appetite Depressants; Body Weight; Clinical Trials as Topic; Consumer Behavior; Dextroampheta | 1973 |
Depression of growth in hyperactive children on stimulant drugs.
Topics: Body Height; Body Weight; Child; Clinical Trials as Topic; Dextroamphetamine; Growth; Humans; Hyperk | 1972 |
Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms.
Topics: Aggression; Amphetamine; Attention; Body Weight; Child; Clinical Trials as Topic; Dextroamphetamine; | 1972 |
Anorexigenic activity of intermittent dextroamphetamine with and without meprobamate.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Weight; Central Nervous System; Clinical Trials as | 1972 |
A controlled study of the effects of group discussions and an anorexiant in outpatient treatment of obesity. With attention to the psychological aspects of dieting.
Topics: Adolescent; Adult; Body Weight; Clinical Trials as Topic; Dextroamphetamine; Diet, Reducing; Female; | 1966 |
160 other studies available for dextroamphetamine and Body Weight
| Article | Year |
|---|---|
Linked Aryl Aryloxypropanolamines as a new class of lipid catabolis agents.
Topics: Adipose Tissue; Animals; Appetite Depressants; Body Weight; Dogs; Eating; Female; Lipid Metabolism; | 1978 |
Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR).
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Body Weight; Dextroamphetamine; Feeding Behavior; | 2017 |
Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study.
Topics: Absorptiometry, Photon; Adiposity; Age Factors; Anthropometry; Attention Deficit Disorder with Hyper | 2016 |
Chronic variable stress prevents amphetamine-elicited 50-kHz calls in rats with low positive affectivity.
Topics: Affect; Animals; Biogenic Monoamines; Body Weight; Dextroamphetamine; Dopamine; Food Preferences; Fr | 2016 |
Longitudinal magnetic resonance imaging reveals striatal hypertrophy in a rat model of long-term stimulant treatment.
Topics: Animals; Body Weight; Central Nervous System Stimulants; Dextroamphetamine; Hypertrophy; Lisdexamfet | 2016 |
Effects of lisdexamfetamine dimesylate treatment for ADHD on growth.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight; Central Ne | 2010 |
Effects of lisdexamfetamine dimesylate treatment for ADHD on growth.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight; Central Ne | 2010 |
Effects of lisdexamfetamine dimesylate treatment for ADHD on growth.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight; Central Ne | 2010 |
Effects of lisdexamfetamine dimesylate treatment for ADHD on growth.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight; Central Ne | 2010 |
Early life stress exacerbates cognitive dysfunction induced by d-amphetamine: amelioration by valproic acid.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Body Weight; Central Nervous System S | 2012 |
Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys.
Topics: Animals; Behavior, Animal; Body Weight; Central Nervous System Stimulants; Cocaine-Related Disorders | 2003 |
Slowing of growth in height and weight on stimulants: a characteristic pattern.
Topics: Adolescent; Age Distribution; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weigh | 2003 |
MECHANISM OF THE DIURETIC ACTION OF D-AMPHETAMINE.
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Aldosterone; Biomedical Research; Body Weight; Creat | 1964 |
[Loss of weight with dexedrine in medical practice].
Topics: Amphetamine; Amphetamines; Body Weight; Dextroamphetamine; Obesity | 1960 |
The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.
Topics: Animals; Animals, Newborn; Apomorphine; Body Weight; Corpus Striatum; Dextroamphetamine; Dopamine; D | 2005 |
Amphetamine- and scopolamine-induced locomotor activity following treatment with chlorphenvinphos or chlorphyriphos in rats.
Topics: Acetylcholinesterase; Animals; Body Weight; Chlorfenvinphos; Cholinesterase Inhibitors; Dextroamphet | 2005 |
Differential effects on prepulse inhibition of withdrawal from two different repeated administration schedules of amphetamine.
Topics: Animals; Biogenic Monoamines; Body Weight; Central Nervous System Stimulants; Chromatography, High P | 2006 |
Effects of central leptin infusion on the reward-potentiating effect of D-amphetamine.
Topics: Animals; Behavior, Animal; Body Weight; Central Nervous System Stimulants; Dextroamphetamine; Drug A | 2006 |
Early life tactile stimulation changes adult rat responsiveness to amphetamine.
Topics: Animals; Animals, Newborn; Body Weight; Central Nervous System Stimulants; Dextroamphetamine; Dopami | 2006 |
The effects of anorexic drugs on free-fed rats responding under a second-order FI15-min (FR10:S) schedule for high incentive foods.
Topics: Animals; Appetite; Appetite Depressants; Appetitive Behavior; Body Weight; Dextroamphetamine; Dose-R | 2007 |
Dexedrine and weight control in pregnancy.
Topics: Body Weight; Dextroamphetamine; Female; Humans; Pregnancy | 1949 |
[Pharmacodynamic study of amphetamine para-chlorophenoxyacetate].
Topics: Amphetamine; Animals; Blood Pressure; Body Weight; Central Nervous System; Dextroamphetamine; Dogs; | 1966 |
Difference in oral effectiveness of two tyrosine hydroxylase inhibitors.
Topics: Animals; Body Weight; Brain; Brain Chemistry; Dextroamphetamine; Diet; Dopamine; Eating; Enzymes; Ma | 1967 |
Pharmacologic studies with 3-(phenylpropoxy)guanidine cyclohexanesulfamate.
Topics: Animals; Appetite; Appetite Depressants; Behavior, Animal; Blood Pressure; Body Weight; Brain; Cats; | 1967 |
Effects of gestational and perinatal exposure to chlordecone (Kepone) on the neurobehavioral development of Fischer-344 rats.
Topics: Animals; Apomorphine; Behavior, Animal; Body Weight; Chlordecone; Dextroamphetamine; Female; Growth; | 1982 |
Neurobehavioral effects following a single dose of chlordecone (Kepone) administered neonatally to rats.
Topics: Animals; Animals, Newborn; Apomorphine; Behavior, Animal; Body Weight; Chlordecone; Conditioning, Op | 1982 |
Elevation of Met5-enkephalin and beta-endorphin hypothalamic content in rats receiving anorectic drugs: differences between D-fenfluramine and D-amphetamine.
Topics: Animals; beta-Endorphin; Body Weight; Brain; Dextroamphetamine; Endorphins; Enkephalin, Methionine; | 1982 |
Effects of hepatic denervation on the anorexic response to epinephrine, amphetamine, and lithium chloride: a behavioral identification of glucostatic afferents.
Topics: Afferent Pathways; Animals; Blood Glucose; Body Weight; Chlorides; Denervation; Dextroamphetamine; D | 1982 |
Effects of d-amphetamine and apomorphine upon operant behavior and schedule-induced licking in rats with 6-hydroxydopamine-induced lesions of the nucleus accumbens.
Topics: Animals; Apomorphine; Behavior, Animal; Body Weight; Brain Chemistry; Conditioning, Operant; Dextroa | 1983 |
An analysis of behavioural mechanisms involved in the acquisition of amphetamine anorectic tolerance.
Topics: Animals; Appetite Depressants; Behavior, Animal; Body Weight; Conditioning, Classical; Conditioning, | 1983 |
Changes in motor activity with age and the effects of pharmacologic treatment.
Topics: Aging; Animals; Body Weight; Dextroamphetamine; Dihydroergotoxine; Female; Meclofenoxate; Motor Acti | 1984 |
Indomethacin potentiates the operant behavior suppressant and rectal temperature lowering effects of low doses of d-amphetamine in rats.
Topics: Animals; Body Temperature; Body Weight; Brain; Conditioning, Operant; Dextroamphetamine; Drug Synerg | 1984 |
Side effects of dextroamphetamine and methylphenidate in hyperactive children--a brief review.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Body Weight; Child; Dextroamphetamine; Grow | 1984 |
Cortisol response to dextroamphetamine stimulation in depressed outpatients.
Topics: Adult; Age Factors; Body Weight; Depressive Disorder; Dextroamphetamine; Female; Humans; Hydrocortis | 1984 |
Tolerance to amphetamine anorexia: role of learning versus body weight settling point.
Topics: Animals; Appetite; Body Weight; Conditioning, Psychological; Dextroamphetamine; Drinking; Drug Toler | 1983 |
Operant regulation of feeding: a static analysis.
Topics: Animals; Body Weight; Conditioning, Operant; Dextroamphetamine; Feeding Behavior; Female; Rats; Rein | 1983 |
Effects of acrylamide on locomotion and central monoamine function in the rat.
Topics: Acrylamide; Acrylamides; Animals; Apomorphine; Biogenic Amines; Body Fluids; Body Weight; Brain Chem | 1983 |
Caffeine pretreatment: enhancement and attenuation of d-amphetamine-induced activity.
Topics: Animals; Body Weight; Caffeine; Dextroamphetamine; Drug Interactions; Male; Motor Activity; Rats | 1984 |
Effects of prenatal amphetamine exposure on the development of behavior in rats.
Topics: Animals; Body Weight; Dextroamphetamine; Female; Motor Activity; Pregnancy; Prenatal Exposure Delaye | 1981 |
Alteration of the disruptive effect of fenfluramine on food consumption in the rat by repeated post-session administration of d-amphetamine.
Topics: Animals; Body Weight; Dextroamphetamine; Drug Interactions; Drug Tolerance; Feeding Behavior; Fenflu | 1981 |
Maternal use of dextroamphetamine and growth of the fetus.
Topics: Birth Weight; Blood Pressure; Body Weight; Dextroamphetamine; Female; Fetus; Gestational Age; Growth | 1983 |
1,3-Diaryltriazenes: a new class of anorectic agents.
Topics: Animals; Appetite Depressants; Body Weight; Dextroamphetamine; Dogs; Dose-Response Relationship, Dru | 1983 |
Effect of three anorectic drugs on central catecholamine levels and synthesis in the Zucker rat.
Topics: alpha-Methyltyrosine; Animals; Appetite Depressants; Body Weight; Brain Chemistry; Catecholamines; D | 1983 |
Maturation and d-amphetamine-induced changes in web building.
Topics: Age Factors; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Dextroamphetamine; Female | 1982 |
Regional brain distribution of alpha-amphetamine in lead-exposed rats.
Topics: Animals; Body Weight; Brain; Dextroamphetamine; Female; Lead; Lead Poisoning; Male; Motor Activity; | 1982 |
Amphetamine anorexia and hypothalamic catecholamines in genetically obese mice (obob).
Topics: Animals; Blood Glucose; Body Weight; Dextroamphetamine; Dopamine; Dose-Response Relationship, Drug; | 1982 |
Enhanced amphetamine anorexia, but not drinking suppression in obese Zucker rats.
Topics: Animals; Body Weight; Dextroamphetamine; Drinking; Eating; Female; Obesity; Rats; Rats, Zucker | 1982 |
Hyperactivity in developing rats: sex differences in 6-hydroxydopamine and amphetamine effects.
Topics: Animals; Body Weight; Brain Chemistry; Dextroamphetamine; Dopamine; Female; Humans; Hydroxydopamines | 1981 |
Effects of amphetamine and phenylpropanolamine on food intake in rats with ventromedial hypothalamic or dorsolateral tegmental damage.
Topics: Animals; Body Weight; Dextroamphetamine; Diet; Dietary Fats; Feeding Behavior; Female; Hypothalamus; | 1980 |
The effects of lead, d-amphetamine, and time of day on activity levels in the mouse.
Topics: Animals; Body Weight; Dextroamphetamine; Lead; Light; Male; Mice; Mice, Inbred Strains; Motor Activi | 1981 |
Postnatal exposure to benzene alters the neurobehavioral functioning of rats when tested during adulthood.
Topics: Animals; Animals, Newborn; Benzene; Body Weight; Brain; Dextroamphetamine; Exploratory Behavior; Fem | 1980 |
Anorexic effects of ethanolamine-O-sulfate and muscimol in the rat: evidence that GABA inhibits ingestive behavior.
Topics: 4-Aminobutyrate Transaminase; Animals; Appetite Depressants; Body Weight; Brain Chemistry; Dextroamp | 1980 |
Investigations of fetal development models for prenatal drug exposure and schizophrenia. Prenatal d-amphetamine effects upon early and late juvenile behavior in the rat.
Topics: Animals; Behavior, Animal; Body Weight; Catalepsy; Dextroamphetamine; Disease Models, Animal; Extinc | 1994 |
Effects of designer drugs on the chicken embryo and 1-day-old chicken.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Animals, Newborn; Body Weight; Chick Embryo; Chickens; Desig | 1994 |
Opioid peptides, adrenocorticotrophic hormone, and idiopathic (orthostatic) edema.
Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; beta-Endorphin; Blood Urea Nitrogen; Body Weight; D | 1994 |
An investigation into the role of the pedunculopontine tegmental nucleus in the mediation of locomotion and orofacial stereotypy induced by d-amphetamine and apomorphine in the rat.
Topics: Animals; Apomorphine; Body Weight; Dextroamphetamine; Drinking; Eating; Feeding Behavior; Ibotenic A | 1994 |
Prenatal cocaine exposure affects the acoustic startle response in adult rat.
Topics: Animals; Body Weight; Central Nervous System Stimulants; Cocaine; Dextroamphetamine; Drinking; Eatin | 1996 |
Sexual segregation in infant mice: behavioural and neuroendocrine responses to d-amphetamine administration.
Topics: Aging; Animals; Behavior, Animal; Body Weight; Central Nervous System Stimulants; Corticosterone; De | 1997 |
Elevated novelty seeking and peculiar d-amphetamine sensitization in periadolescent mice compared with adult mice.
Topics: Aging; Analysis of Variance; Animals; Body Weight; Central Nervous System Stimulants; Corticosterone | 1998 |
The effects of cadmium contamination on the discriminative stimulus properties of cocaine and related drugs.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Benzazepines; Body | 1999 |
Effect of d-amphetamine repeated administration on rat antioxidant defences.
Topics: Animals; Body Weight; Cysteine; Dextroamphetamine; Drinking; Eating; Liver; Male; Organ Specificity; | 1999 |
Loss of tolerance to amphetamine-induced hypophagia in rats: homeostatic readjustment vs. instrumental learning.
Topics: Animals; Appetite Depressants; Body Weight; Conditioning, Operant; Dextroamphetamine; Drug Tolerance | 1999 |
Striatal dopamine sensitization to D-amphetamine in periadolescent but not in adult rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Behavior, Animal; Body Weight; Brain Chemistry; Caud | 2001 |
Therapeutic self-medication as a context for drug abuse research.
Topics: Adult; Body Weight; Dextroamphetamine; Drug Prescriptions; Female; Fenfluramine; Humans; Male; Metha | 1978 |
Neuropathology of "spinning syndrome" induced by prenatal intoxication with a PCB in mice.
Topics: Animals; Animals, Newborn; Apomorphine; Body Weight; Central Nervous System Diseases; Cranial Nerves | 1979 |
A new device for the simultaneous measurement of locomotor and stereotypic frequency in mice.
Topics: Animals; Behavior; Body Weight; Cocaine; Dextroamphetamine; Humans; Male; Methylphenidate; Mice; Mic | 1979 |
The pharmacological and anatomical substrates of the amphetamine response in the rat.
Topics: Animals; Apomorphine; Behavior, Animal; Body Weight; Cerebral Cortex; Cocaine; Dextroamphetamine; Dr | 1975 |
Idiopathic edema as a cause of nonarticular rheumatism.
Topics: Adult; Body Weight; Capillary Permeability; Chlorthalidone; Dextroamphetamine; Edema; Female; Humans | 1979 |
A pharmacological study of changes in central nervous system receptor responsiveness after long-term dexamphetamine and apomorphine administration.
Topics: Animals; Apomorphine; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Body Weight; Central Ner | 1978 |
Cholecystokinin, amphetamine and diazepam and feeding in lean and obese Zucker rats.
Topics: Animals; Body Weight; Cholecystokinin; Dextroamphetamine; Diazepam; Drug Interactions; Feeding Behav | 1979 |
Drug induced activity in lead-exposed mice.
Topics: Age Factors; Animals; Apomorphine; Body Weight; Brain Chemistry; Dextroamphetamine; Drinking Behavio | 1979 |
The effects of stimulant medication on the growth of hyperkinetic children.
Topics: Adolescent; Body Height; Body Weight; Child Behavior Disorders; Dextroamphetamine; Growth; Growth Di | 1979 |
Neonatal treatment of hamsters with barbiturate alters adult sexual behavior.
Topics: Animals; Animals, Newborn; Body Weight; Copulation; Cricetinae; Dextroamphetamine; Ejaculation; Fema | 1979 |
Effects of carbon disulfide on motor function and responsiveness to d-amphetamine in rats.
Topics: Animals; Body Weight; Carbon Disulfide; Dextroamphetamine; Hindlimb; Male; Motor Activity; Rats; Rat | 1979 |
Variability in development of tolerance to repeated injections of low doses of dl-amphetamine in rats.
Topics: Amphetamine; Animals; Behavior, Animal; Body Temperature; Body Weight; Circadian Rhythm; Dextroamphe | 1977 |
Early handling and maternal behavior: effect on d-amphetamine responsiveness in rats.
Topics: Animals; Body Weight; Dextroamphetamine; Female; Handling, Psychological; Humans; Male; Maternal Beh | 1978 |
Resistance of alloxan-diabetic rats to the behavioral activation induced by d-amphetamine: partial restoration with a high fat/protein diet.
Topics: Alloxan; Animals; Behavior, Animal; Blood Glucose; Body Weight; Brain; Dextroamphetamine; Diabetes M | 1978 |
The effects of d-amphetamine and temperature on p-cresol and pentylenetetrazol induced convulsions.
Topics: Animals; Body Weight; Cresols; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship | 1977 |
Intravenous self-administration of drugs in rats.
Topics: Animals; Behavior, Animal; Body Weight; Chlorpromazine; Dextroamphetamine; Drinking; Dronabinol; Eat | 1978 |
The role of undernutrition in animal models of hyperactivity.
Topics: Animals; Body Weight; Dextroamphetamine; Female; Growth; Lead; Male; Mice; Motor Activity; Nutrition | 1978 |
Barbiturate and amphetamine activity in rats fed a magnesium-deficient diet.
Topics: Animals; Body Weight; Dextroamphetamine; Diet; Hexobarbital; Hypnotics and Sedatives; Lethal Dose 50 | 1978 |
Schedule induced self-injection of D-amphetamine by naive animals.
Topics: Animals; Body Weight; Dextroamphetamine; Male; Rats; Reinforcement Schedule; Self Administration | 1978 |
Long-and short-term regulation of feeding patterns in the rat.
Topics: Animals; Appetite Regulation; Body Weight; Circadian Rhythm; Dextroamphetamine; Feeding Behavior; Fe | 1977 |
Behavioral effects of a lesion in the ventral mesencephalic tegmentum: evidence for involvement of A10 dopaminergic neurons.
Topics: Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Body Weight; Brain Chemistry; Dextroamph | 1977 |
Preclinical evaluation of DITA [3',4'-dichloro-2-(2-imidazolin-2-yl-thio)acetophenone hydrobromide]: a new anorexigenic agent.
Topics: Acetophenones; Animals; Appetite Depressants; Body Weight; Cats; Dextroamphetamine; Diethylpropion; | 1977 |
A mobilizable pool of d-amphetamine in adipose after daily administration to rats.
Topics: Adipose Tissue; Animals; Body Weight; Brain Chemistry; Dextroamphetamine; Male; Rats; Stress, Physio | 1977 |
Effect of acute and chronic injections of amphetamine on intracranial self-stimulation (ICS) and some aryl alkyl amines and the rat brain.
Topics: Animals; Body Weight; Brain; Corpus Striatum; Dextroamphetamine; Drug Tolerance; Hypothalamus; Male; | 1976 |
Alpha-flupenthixol-induced hyperactivity by chronic dosing in rats.
Topics: Animals; Apomorphine; Body Weight; Dextroamphetamine; Female; Flupenthixol; Humans; Motor Activity; | 1976 |
Tolerance to amphetamine in two species (rat and guinea pig) that metabolize it differently.
Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Corpus Striatum; Dextroamphetamine; Dopami | 1976 |
Factors influencing tolerance to d-amphetamine-induced anorexia in rats.
Topics: Animals; Appetite Depressants; Body Weight; Dextroamphetamine; Drug Tolerance; Eating; Female; Food | 1976 |
Interactions of amygdala lesions with effects of pilocarpine and d-amphetamine on mouse killing, feeding, and drinking in rats.
Topics: Aggression; Amygdala; Animals; Behavior, Animal; Body Weight; Dextroamphetamine; Dose-Response Relat | 1976 |
Growth rebound after termination of stimulant drugs.
Topics: Adolescent; Body Height; Body Weight; Child; Dextroamphetamine; Female; Humans; Hyperkinesis; Male; | 1975 |
Proceedings: Effect of forced self-administration with D-amphetamine on food intake, body weight and amino acid incorporation into liver and brain proteins.
Topics: Amino Acids; Animals; Appetite; Body Weight; Cerebral Cortex; Dextroamphetamine; Microsomes, Liver; | 1975 |
Food-deprivation-induced behavioral arousal: mediation by hypothalamus and amygdala.
Topics: Amygdala; Animals; Arousal; Body Weight; Dextroamphetamine; Diabetes Mellitus, Experimental; Drinkin | 1975 |
Some effects of prenatal exposure to d-amphetamine sulfate and phenobarbital on developmental neurochemistry and on behavior.
Topics: Animals; Avoidance Learning; Behavior, Animal; Birth Weight; Body Weight; Brain; Brain Chemistry; Co | 1975 |
Effects of d-amphetamine sulfate on aggressive behavior in laboratory mice.
Topics: Aggression; Animals; Body Weight; Dextroamphetamine; Female; Fertility; Humans; Litter Size; Male; M | 1975 |
Effects of drug experience on drug induced conditioned taste aversions: studies with amphetamine and fenfluramine.
Topics: Animals; Avoidance Learning; Body Weight; Choice Behavior; Conditioning, Psychological; Dextroamphet | 1975 |
Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series.
Topics: Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Benzimidazoles; Blepharoptosis; Body Tem | 1975 |
The effect of chronic self-administration of d-amphetamine on food intake, locomotor activity, and C14-leucine incorporation into cerebral cortex protein.
Topics: Animals; Body Weight; Cerebral Cortex; Dextroamphetamine; Drug Tolerance; Eating; Female; Motor Acti | 1976 |
Effects of amphetamine on food intake and weight: timing of injections and food access.
Topics: Animals; Body Weight; Dextroamphetamine; Eating; Food; Injections; Male; Rats; Rats, Sprague-Dawley | 1992 |
Regulatory behaviour, exploration and locomotion following NMDA or 6-OHDA lesions in the rat nucleus accumbens.
Topics: Animals; Apomorphine; Body Weight; Brain Mapping; Dextroamphetamine; Dopamine; Dose-Response Relatio | 1992 |
The effects of amphetamine on body weight and energy expenditure.
Topics: Animals; Body Weight; Calorimetry, Indirect; Circadian Rhythm; Dextroamphetamine; Eating; Energy Int | 1992 |
A new motor test sensitive to aging and dopaminergic function.
Topics: Aging; Animals; Body Weight; Dextroamphetamine; Dopamine; Haloperidol; Levodopa; Male; Motor Activit | 1991 |
Parker and Radow test of drug withdrawal aversion: opposite effect in rats chronically infused with sufentanil or amphetamine.
Topics: Analgesics, Opioid; Animals; Body Weight; Choice Behavior; Dextroamphetamine; Fentanyl; Infusion Pum | 1990 |
Effects of dietary tyrosine on L-dopa- and amphetamine-induced changes in locomotor activity and neurochemistry in mice.
Topics: Animals; Biogenic Monoamines; Body Weight; Brain Chemistry; Dextroamphetamine; Diet; Drug Interactio | 1990 |
Effects of acute administration of diazepam and d-amphetamine on aggressive and escape responding of normal male subjects.
Topics: Aggression; Avoidance Learning; Body Weight; Dextroamphetamine; Diazepam; Dose-Response Relationship | 1990 |
Delayed effects of amphetamine or phencyclidine: interaction of food deprivation, stress and dose.
Topics: Adipose Tissue; Animals; Body Weight; Dextroamphetamine; Dose-Response Relationship, Drug; Electrosh | 1990 |
Super-reactivity to amphetamine toxicity induced by schedule of reinforcement.
Topics: Animals; Body Weight; Conditioning, Operant; Dextroamphetamine; Diuresis; Drinking; Eating; Male; Ra | 1990 |
Evaluation of long-term consequences in behavioral and/or neural function following neonatal chlordecone exposure.
Topics: Animals; Animals, Newborn; Behavior, Animal; Body Weight; Chlordecone; Dextroamphetamine; Female; Ha | 1985 |
Lack of self-administration of different fenfluramine isomers in rats.
Topics: Animals; Arousal; Body Weight; Dextroamphetamine; Dose-Response Relationship, Drug; Fenfluramine; Hu | 1989 |
Amphetamine enantiomers and rat consummatory behavior: a new perspective.
Topics: Amphetamines; Animals; Body Weight; Dextroamphetamine; Drinking; Drug Tolerance; Eating; Injections, | 1989 |
Metaphit, a proposed phencyclidine (PCP) antagonist, prevents PCP-induced locomotor behavior through mechanisms unrelated to specific blockade of PCP receptors.
Topics: Animals; Body Weight; Brain Chemistry; Dextroamphetamine; Dopamine; Injections; Injections, Intraven | 1987 |
Growth hormone-releasing factor stimulation test in depression.
Topics: Adult; Age Factors; Body Weight; Clonidine; Depressive Disorder; Dextroamphetamine; Female; Growth H | 1988 |
An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Calcitonin; Dextroamphetamine; Drug Toleran | 1987 |
Postnatal behavioural effects of maternal nicotine exposure in rats.
Topics: Animals; Behavior, Animal; Body Weight; Dextroamphetamine; Drinking; Eating; Female; Motor Activity; | 1988 |
Comparison of the effect of common decongestant agents and amphetamine on fighting behavior and weight change.
Topics: Aggression; Animals; Body Weight; Dextroamphetamine; Ephedrine; Mice; Phenylephrine; Phenylpropanola | 1988 |
Dietary modulation of oral amphetamine intake in rats.
Topics: Administration, Oral; Animals; Body Weight; Dextroamphetamine; Dose-Response Relationship, Drug; Dri | 1988 |
Amphetamine's effects on food consumption and body weight: the role of adaptive processes.
Topics: Animals; Body Weight; Dextroamphetamine; Drug Tolerance; Eating; Hunger; Male; Rats; Rats, Inbred St | 1988 |
Effects of body weight on discriminative-stimulus control by phencyclidine in the pigeon.
Topics: Animals; Body Weight; Columbidae; Conditioning, Classical; Dextroamphetamine; Discrimination Learnin | 1987 |
The effect of phenylpropanolamine and amphetamine on fighting behavior and weight change in mice.
Topics: Aggression; Animals; Body Weight; Dextroamphetamine; Mice; Phenylpropanolamine | 1987 |
Effect of mazindol, d-amphetamine and diethylpropion on purine nucleotide binding to brown adipose tissue.
Topics: Adipose Tissue, Brown; Animals; Body Weight; Dextroamphetamine; Diethylpropion; Dose-Response Relati | 1986 |
Amphetamine: effects on meal patterns and macronutrient selection.
Topics: alpha-Methyltyrosine; Animals; Body Weight; Dextroamphetamine; Dopamine; Epinephrine; Feeding Behavi | 1986 |
Long lasting behavioral effects of dimethyl sulfoxide and the "peripheral" toxicant p-bromophenylacetylurea.
Topics: Animals; Behavior, Animal; Body Weight; Conditioning, Operant; Dextroamphetamine; Dimethyl Sulfoxide | 1985 |
Dietary obesity: effects of drugs on food intake in S 5B/P1 and Osborne-Mendel rats.
Topics: Adenosine; Animals; Appetite; Body Weight; Deoxyglucose; Dextroamphetamine; Eating; Female; Glucose; | 1985 |
Comparative effects of infusions of 6-hydroxydopamine into nucleus accumbens and anterolateral hypothalamus induced by 6-hydroxydopamine on the response to dopamine agonists, body weight, locomotor activity and measures of exploration in the rat.
Topics: Animals; Apomorphine; Body Weight; Brain Chemistry; Dextroamphetamine; Exploratory Behavior; Humans; | 1985 |
Tolerance pattern to amphetamine anorexia after selective lesions in the hypothalamic dopaminergic projection.
Topics: Animals; Anorexia; Body Weight; Dextroamphetamine; Dopamine; Drug Tolerance; Energy Intake; Feeding | 1985 |
Amphetamine tolerance and body weight set point: a dose-response analysis.
Topics: Animals; Body Weight; Dextroamphetamine; Drug Tolerance; Individuality; Male; Rats | 1985 |
Effects of guanethidine sympathectomy on feeding, drinking, weight gain and amphetamine anorexia in the rat.
Topics: Adipose Tissue, Brown; Animals; Body Temperature Regulation; Body Weight; Dextroamphetamine; Drinkin | 1985 |
Enhancement of amphetamine action after interruption of ascending serotonergic pathways.
Topics: Animals; Behavior, Animal; Biogenic Amines; Body Weight; Brain; Brain Chemistry; Chlorpromazine; Dex | 1974 |
Effect of chronic intoxication with (+)-amphetamine on its concentration in liver and brain and on (14C) leucine incorporation into microsomal and cytoplasmic proteins of rat liver.
Topics: Animals; Body Weight; Brain; Carbon Radioisotopes; Cytoplasm; Dextroamphetamine; Drug Tolerance; Leu | 1974 |
[Comparative studies on some effects of amphetamine in rats of different ages].
Topics: Age Factors; Animals; Body Temperature; Body Weight; Brain; Brain Chemistry; Corticosterone; Dextroa | 1970 |
Hyperuricemia in a child: a complication of treatment of obesity.
Topics: Acetone; Blood Chemical Analysis; Body Height; Body Weight; Child; Dextroamphetamine; Diabetes Melli | 1974 |
Inhibition of amphetamine tolerance and metabolism by propranolol.
Topics: Animals; Body Weight; Dextroamphetamine; Drug Tolerance; Kinetics; Male; Propranolol; Rats; Time Fac | 1974 |
Effects of d-amphetamine sulfate given to pregnant mice on activity and on catecholamines in the brains of offspring.
Topics: Animals; Birth Weight; Body Weight; Brain Chemistry; Dextroamphetamine; Dopamine; Female; Fertility; | 1974 |
Acute and chronic effects of delta9-tetrahydrocannabinol on food intake by rats.
Topics: Animals; Appetite; Appetite Depressants; Body Weight; Cannabis; Dextroamphetamine; Dose-Response Rel | 1974 |
Anorectic acitvity of 4-chloro-2'-((methylamino)methyl)- benzyhydrol HCl, (PR-F-36-Cl).
Topics: Animals; Appetite Depressants; Benzhydryl Compounds; Blood Pressure; Body Weight; Catecholamines; De | 1974 |
Overeating and obesity from damage to a noradrenergic system in the brain.
Topics: Animals; Appetite Regulation; Body Weight; Catecholamines; Denervation; Desipramine; Dextroamphetami | 1973 |
Narcolepsy and cataplexy. Clinical features, treatment and cerebrospinal fluid findings.
Topics: Adult; Amphetamine; Aspartic Acid; Body Weight; Cataplexy; Cerebrospinal Fluid Proteins; Dextroamphe | 1974 |
Comparative study of the anorexigenic activity of 5-(3,4-dichlorophenoxymethyl)-2-amino-2-oxazoline HCl and d-amphetamine in different species.
Topics: Animals; Appetite Depressants; Aurothioglucose; Blood Pressure; Body Weight; Cats; Dextroamphetamine | 1973 |
The effects of anorexic doses of dextro-amphetamine on the ventromedial-hypothalamic hyperphagic rat.
Topics: Animals; Appetite Depressants; Body Weight; Dextroamphetamine; Dose-Response Relationship, Drug; Dri | 1973 |
The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat.
Topics: Animals; Apomorphine; Behavior; Body Weight; Brain; Brain Chemistry; Caudate Nucleus; Dextroamphetam | 1974 |
Amphetamine-type drugs for hyperactive children.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Body Weight; Brain; Child; Dextroamphetamin | 1972 |
Factors influencing the suppressant effects of two stimulant drugs on the growth of hyperactive children.
Topics: Analysis of Variance; Body Height; Body Weight; Child; Dextroamphetamine; Growth Disorders; Humans; | 1973 |
Chronic administration of d-amphetamine and chlorpromazine in rats.
Topics: Animals; Appetite Depressants; Body Weight; Chlorpromazine; Dextroamphetamine; Drug Interactions; Dr | 1973 |
Brain to serum distribution of radioactivity of injected ( 3 H)-d-amphetamine in differentially housed mice.
Topics: Animals; Body Weight; Brain; Brain Chemistry; Crowding; Dextroamphetamine; Housing, Animal; Injectio | 1973 |
[Insulin secretion and hydrocarbon tolerance in essential obesity in women (influence of fenfluramine, phenformin and D-amphetamine)].
Topics: Administration, Oral; Blood Glucose; Body Weight; Dextroamphetamine; Evaluation Studies as Topic; Fe | 1973 |
The effect of thiamine deficiency on the actions of drugs effecting the central nervous system.
Topics: Analgesia; Animals; Appetite; Body Weight; Brain; Chlordiazepoxide; Dextroamphetamine; Lethal Dose 5 | 1973 |
Effects of amphetamine on electroshock responses in developing rats.
Topics: Age Factors; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brain; Brain Chemistry; Dextr | 1974 |
The effects of chronic treatment with d-amphetamine on food intake, body weight, locomotor activity and subcellular distribution of the drug in rat brain.
Topics: Animals; Body Weight; Brain; Cell Nucleus; Centrifugation, Density Gradient; Cytoplasm; Dextroamphet | 1974 |
Independence of the effects of d-amphetamine and food deprivation or body weight on the food consumption of rats.
Topics: Age Factors; Analysis of Variance; Animals; Body Weight; Dextroamphetamine; Dose-Response Relationsh | 1974 |
Enhanced stimulant properties of (+)-amphetamine after chronic reserpine treatment in the rat: mediation by hypophagia and weight loss.
Topics: Analysis of Variance; Animals; Appetite Depressants; Body Weight; Dextroamphetamine; Feeding Behavio | 1972 |
Neuromuscular functions of mature mice following neonatal monosodium glutamate.
Topics: Animals; Animals, Newborn; Body Weight; Crowding; Dextroamphetamine; Female; Food Additives; Glutama | 1971 |
The interaction of amphetamine and body weight on a food-reinforced operant.
Topics: Analysis of Variance; Animals; Body Weight; Conditioning, Operant; Dextroamphetamine; Food; Male; Ra | 1969 |
Pharmacology of phentermine.
Topics: Amphetamine; Animals; Appetite; Appetite Depressants; Blood Pressure; Body Weight; Cardiovascular Sy | 1969 |
Effects of chlorpromazine and d-amphetamine in Long Evans rats of different age, body weight and brain weight.
Topics: Age Factors; Animals; Animals, Newborn; Body Weight; Brain; Brain Chemistry; Chlorpromazine; Dextroa | 1969 |
A determination of the anorexigenic potential of dl-amphetamine, d-amphetamine, l-amphetamine and phentermine.
Topics: Amphetamine; Animals; Appetite; Appetite Depressants; Body Weight; Dextroamphetamine; Drug Tolerance | 1969 |
Facilitating effects of pre- and posttrial amphetamine administration on discrimination learning in mice.
Topics: Animals; Body Weight; Dextroamphetamine; Discrimination Learning; Female; Food Deprivation; Injectio | 1969 |
Pharmacologic and toxicologic studies with the monopotassium salt of acetylenedicarboxylic acid.
Topics: Administration, Oral; Alkynes; Animals; Appetite Depressants; Blood Pressure; Body Weight; Cardiovas | 1970 |
Effects of prenatal administration of psychotropic drugs on behavior of developing rats.
Topics: Animals; Animals, Laboratory; Animals, Newborn; Behavior, Animal; Body Weight; Chlorpromazine; Condi | 1970 |
Correlation of dextroamphetamine excretion and drug response in hyperkinetic children.
Topics: Analysis of Variance; Behavior; Blood Pressure; Body Weight; Child; Child, Preschool; Dextroamphetam | 1968 |
Anorexigenic effects of fenfluramine hydrochloride in rats, guinea pigs, and dogs.
Topics: Animals; Appetite; Appetite Depressants; Appetite Regulation; Behavior, Animal; Body Weight; Dextroa | 1969 |
Effects of chronic d-amphetamine sulfate administration during development in rats.
Topics: Animals; Avoidance Learning; Body Weight; Conditioning, Psychological; Dextroamphetamine; Drug Toler | 1969 |
Influence of various psychoactive drugs on the in vivo metabolism of d-amphetamine in the rat.
Topics: Animals; Antidepressive Agents; Body Temperature; Body Weight; Dextroamphetamine; Drug Synergism; Hy | 1969 |